Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 12;23(20):12139. doi: 10.3390/ijms232012139

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Antiangiogenic agents combined with PDL and a novel PDT for treatment of PWSs: (A) axitinib inhibits the mRNA levels of HIF-1α, VEGF, Ccl2, Plau, and MMP19 increased by PDL. In addition to this, it also blocks PDL-induced pERK, pAKT, and pP70S6K. The expression of VEGF and ANGPT2 decreased in the PDL combined with the imiquimod sample, compared with PDL alone. RPM inhibits the PDL-induced expression of Ki-67, nestin, HIF-1α, VEGF, P70S6K, etc.; (B) a novel PDT for treatment of PWSs: photosensitizers (ICG, IR-780, IR-783) are encapsulated inside nanocarriers, which are conjugated with special markers (CD133/CD166/EphB1/EfnB2/VEGFR-2).